Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2016

View Archived Issues

NYMC and Interprotein collaborate on C2 domain-interactive therapeutics

Theranexus obtains funding for development of THN-201

Bayer and Evotec establish 5-year research partnership in kidney disease

Regen BioPharma's NR2F6 modulators show positive preclinical results

Abilita Bio awarded grant from NCI

Takeda and Affilogic establish Nanofitins research collaboration for neurological disorders

NuSirt and OWL Metabolomics partner to develop companion diagnostic for NS-0200

Chromosome 1 variant is associated with increased risk of IFN-beta-induced liver injury

NIH award supports Symbiotix's development of PSA for IBD

Novel model for the development of phages that target pathogenic bacteria

Artios Pharma launched to focus on developing novel DNA damage response cancer therapies

Allergan acquires Akarna Therapeutics

AstraZeneca withdraws MAA for cediranib

Aurigene Discovery Technologies patents PD-1 signaling inhibitors

Sunshine Lake Pharma discloses HCV inhibitors

Eleven Biotherapeutics acquires Viventia Bio

Nanjing Sanhome Pharmaceutical describes PI3Kdelta inhibitors

Medshine Discovery develops CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Melinta Therapeutics presents antibacterials

Quest Diagnostics launches Zika antibody test service

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Newron re-submits Xadago NDA

Regulus begins phase II trial of RG-012 in Alport syndrome

Takeda presents phase II results for TAK-448 in men with T2D and HH

Kadmon initiates phase II trials of KD-025 in psoriasis and GvHD

FDA approves Janssen Pharmaceuticals' Invokamet XR

Gilead stops phase II/III study of GS-5745 in ulcerative colitis based on DMC review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...